Journal of the American Society of Nephrology, Vol 6, 154-164, Copyright © 1995 by American Society of Nephrology

REVIEWS

Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties

BP Sawaya, JP Briggs and J Schnermann

Amphotericin B (AmB) has been in clinical use for more than 30 yr but has remained the most effective drug for treatment of serious fungal infections. Its use has increased in recent years, as the result of increases in aggressive intensive care support and increased numbers of immunocompromised patients. Nephrotoxic manifestations are common, and this is the major factor limiting the clinical use of the drug. A number of recent studies have contributed to a better understanding of the mechanism by which AmB exerts its nephrotoxic effect. AmB alters cell membrane permeability and probably as a consequence alters tubular and vascular smooth muscle cell function, leading to various tubular transport defects and vasoconstriction. Decreased RBF appears to play a major role in AmB-induced reduction GFR, and recurrent ischemia may be the basis of permanent structural nephrotoxic effects. Salt loading is the only measure proven by controlled prospective study to ameliorate AmB nephrotoxicity in humans. Liposomal AmB and the formulation of an emulsion of AmB in lipid may provide a protective effect based on altering the affinity of AmB for mammalian cell membranes, while preserving high efficacy against fungal cells. However, further studies are needed to evaluate the efficacy and safety of these new AmB formulations.

This article has been cited by other articles:

				S. Mohan, S. Ahmed, B. Alimohammadi, M. Jaitly, J.-T. Cheng, and V. A. Pogue Proteinuria lowers the risk of amphotericin B-associated hypokalaemia J. Antimicrob. Chemother., September 1, 2007; 60(3): 690 - 693. [Abstract] [Full Text] [PDF]

				F. G. Silva Chemical-Induced Nephropathy: A Review of the Renal Tubulointerstitial Lesions in Humans Toxicol Pathol, February 1, 2004; 32(2_suppl): 71 - 84. [Abstract] [PDF]

				A. H. Groll, D. Mickiene, V. Petraitis, R. Petraitiene, R. M. Alfaro, C. King, S. C. Piscitelli, and T. J. Walsh Comparative Drug Disposition, Urinary Pharmacokinetics, and Renal Effects of Multilamellar Liposomal Nystatin and Amphotericin B Deoxycholate in Rabbits Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3917 - 3925. [Abstract] [Full Text] [PDF]

				E. Gerbaud, F. Tamion, C. Girault, K. Clabault, S. Lepretre, J. Leroy, and G. Bonmarchand Persistent acute tubular toxicity after switch from conventional amphotericin B to liposomal amphotericin B (Ambisome) J. Antimicrob. Chemother., February 1, 2003; 51(2): 473 - 475. [Full Text] [PDF]

				G. Delmas, S. Park, Z. W. Chen, F. Tan, R. Kashiwazaki, L. Zarif, and D. S. Perlin Efficacy of Orally Delivered Cochleates Containing Amphotericin B in a Murine Model of Aspergillosis Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2704 - 2707. [Abstract] [Full Text] [PDF]

				H. P. Burghoorn, P. Soteropoulos, P. Paderu, R. Kashiwazaki, and D. S. Perlin Molecular Evaluation of the Plasma Membrane Proton Pump from Aspergillus fumigatus Antimicrob. Agents Chemother., March 1, 2002; 46(3): 615 - 624. [Abstract] [Full Text] [PDF]

				R. Santangelo, P. Paderu, G. Delmas, Z.-W. Chen, R. Mannino, L. Zarif, and D. S. Perlin Efficacy of Oral Cochleate-Amphotericin B in a Mouse Model of Systemic Candidiasis Antimicrob. Agents Chemother., September 1, 2000; 44(9): 2356 - 2360. [Abstract] [Full Text]

				C. E. Gonzalez, A. H. Groll, N. Giri, D. Shetty, I. Al-Mohsen, T. Sein, E. Feuerstein, J. Bacher, S. Piscitelli, and T. J. Walsh Antifungal Activity of the Pradimicin Derivative BMS 181184 in the Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits Antimicrob. Agents Chemother., September 1, 1998; 42(9): 2399 - 2404. [Abstract] [Full Text]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673